Pancreatic-cancer-targeting nucleic acid polypeptide nanodrug and preparation method thereof

Abstract

The invention discloses a pancreatic-cancer-targeting nucleic acid polypeptide nanodrug and a preparation method thereof; a pancreatic-cancer-targeting polypeptide and miRNA are self-assembled into anano composite, including two parts; the part I is chimeric peptide PL-1 that is formed of a pancreatic-cancer-targeting polypeptide which fuses a pancreatic cancer specific polypeptide and nine N ends of D- or L-arginine residue through four glycine linkers; the part II is chimeric peptide PL-1 that captures anionic miRNA through electrostatic interaction to form the nano composite through self-assembly. The pancreatic-cancer-targeting nucleic acid polypeptide nanodrug and the preparation method thereof have the advantages that both in-vivo and in-vitro experiments indicate that the nanodrug,nanoparticles, has specific targeting affinity to pancreatic cancer and can significantly enhance therapeutic effect of chemotherapeutic drugs, technical support and preclinical study basis can be provided for the clinical development of novel pancreatic-cancer-targeting drugs, and a novel concept can also be provided for the research and development of other antitumor drugs by combining polypeptides and miRNA to generate a targeting nano preparation.

Description

Technical field [0001] The invention belongs to a nano-particle medicine targeting pancreatic cancer, and is mainly a nucleic acid polypeptide nano-medicine targeting pancreatic cancer and a preparation method thereof. Background technique [0002] Currently, there is no approved drug for pancreatic cancer. However, there are a large number of targeted therapeutic drugs in clinical trials of pancreatic cancer, such as targeted anticancer drugs targeting vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), and tumors targeting the immune system in the tumor environment Vaccines, etc. [0003] The current clinical trial data of targeted drugs applied to pancreatic cancer include: [0004] 1. EGFR target: [0005] Erlotinib, a phase III clinical trial showed that erlotinib combined with gemcitabine can significantly prolong the overall OS of pancreatic cancer patients compared with gemcitabine monotherapy. The median OS was 6.24 and 5.91 months, respectively, an...

AI Technical Summary

Problems solved by technology

[0028] From the above studies, there is still no single targeted drug that has a significant effect on pancreatic cancer; clinical trials in combination with conventional chemotherapy drugs have also shown that no targeted drug can clearly enhance the effect of chemotherapy

Clinically, there is currently no targeted drug for pancreatic cancer approved for use in patients with pancreatic cancer.

Images